Affymetrix, BioDiscovery launches new analysis software for research on cancer -
Affymetrix: ad (Nasdaq AFFX) and BioDiscovery, Inc. today announced the launch of a new analysis software, Nexus Copy Number for Affymetrix, which is specifically for data generated by the platforms of genetic analysis Affymetrix 'in cancer research, including CytoScan ® and cytogenetic Suite OncoScan ® FFPE Assay Kit.
"CytoScan cytogenetic Suite and OncoScan FFPE Assay Kit are key elements of our cancer portfolio," said Dr. Andy Last, Executive Vice President and Chief Operating Officer of Affymetrix. "The researchers found CNV and copy neutral changes in samples of solid and liquid tumors. With the use of Nexus Copy Number, an advanced discovery tool to query large sets of data, the researchers were able to identify biomarkers that drive disease progression. The new Nexus Copy Number Affymetrix software offers researchers a software version Nexus Copy Number which is easier to access and has been specially designed for testing Affymetrix '. "
" We are delighted to extend our relationship with Affymetrix by this unique product, "said Dr. Soheil Shams, Scientific Director of BioDiscovery. "The high quality data from Affymetrix testing works extremely well in our software to detect the number of variants copies. We have customers all over the world who have been taking advantage of cytogenetics Suite CytoScan and platforms OncoScan for analysis of the number of copies from various types of cancer samples, and we are pleased to offer this joint solution to help scientists gain new information on the biology of cancer. "
EmoticonEmoticon